Table 2 Subgroup analyses of changes in sleep onset latency recorded with the electronic sleep diary
Subgroups | Phases | Changesa | Wilcoxon’s signed rank sum test | ||
|---|---|---|---|---|---|
n | Mean ± SD | 95% CI | P value | ||
Autism spectrum disorder | |||||
 Absent | Screening phase | – | – | – | – |
Medication phase I | 25 | −36.2 ± 40.5 | −53.0 to −19.5 | <  0.0001 | |
 Present | Screening phase | – | – | – | – |
Medication phase I | 74 | −36.8 ± 48.1 | −48.0 to −25.7 | <  0.0001 | |
ADHD | |||||
 Absent | Screening phase | – | – | – | – |
Medication phase I | 39 | −42.7 ± 62.5 | −62.9 to −22.4 | < 0.0001 | |
 Present | Screening phase | – | – | – | – |
Medication phase I | 60 | −32.8 ± 31.2 | −40.9 to −24.7 | < 0.0001 | |
Intellectual disabilities | |||||
 Absent | Screening phase | – | – | – | – |
Medication phase I | 77 | −35.8 ± 44.6 | −46.0 to −25.7 | < 0.0001 | |
 Present | Screening phase | – | – | – | – |
Medication phase I | 22 | −39.7 ± 52.1 | −62.8 to −16.6 | < 0.0001 | |
Motor disorders | |||||
 Absent | Screening phase | – | – | – | – |
Medication phase I | 90 | −37.4 ± 47.9 | −47.4 to −27.3 | < 0.0001 | |
 Present | Screening phase | – |  |  |  |
Medication phase I | 9 | −29.8 ± 19.7 | −45.0 to −14.6 | 0.0039 | |
Specific learning disorder | |||||
 Absent | Screening phase | – | – | – | – |
Medication phase I | 93 | −36.0 ± 47.1 | −45.7 to −26.3 | < 0.0001 | |
 Present | Screening phase | – | – | – | – |
Medication phase I | 6 | −46.8 ± 25.3 | −73.4 to −20.3 | 0.0313 | |